EUVIMEDEUVIMED entdecken
Crossref

Physiologically Based Pharmacokinetic Modeling to Predict the Exposure and Provide Dosage Regimens of Oseltamivir in Pregnant Women with Comorbid CES1 Polymorphism and Hepatic Cirrhosis

Jianwen Xu iD, Shoutian Zhang, Peilin Zhou, Zhikun Zhan, Shuifang Zhou, Yuewen Chen iD, Rongfang Lin, Cuihong Lin

The Journal of Clinical Pharmacology · 2026-11 · 66 (11)

DOI: 10.1002/jcph.70285 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 01.11.2026. Verfasst von Jianwen Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Oseltamivir, Carboxylic Ester Hydrolases, Models, Biological, Antiviral Agents. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Innovation of Science and Technology, Fujian Province, Natural Science Foundation of Fujian Province, Fujian Provincial Health Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oseltamivir (OSE) is widely prescribed for pregnant women with influenza; however, its optimal dosing strategy remains undefined in cases involving carboxylesterase 1 ( CES1 ) gene polymorphism and hepatic cirrhosis. This study aimed to explore OSE dosing regimens for pregnant patients with comorbid CES1 polymorphism and hepatic cirrhosis. A mechanistic physiologically based pharmacokinetic (PBPK) model of OSE was first built and verified in healthy populations, then extrapolated to adult patients with CES1 polymorphism, hepatic cirrhosis, and pregnant patients. The PBPK model successfully predicted and verified the PKs of OSE and its active metabolite oseltamivir carboxylate (OSC) in both non‐pregnant and pregnant women. Simulation results showed that the fold errors of the predicted and observed values of the area under the curve (AUC) and peak plasma concentration (C max ) values ranged from 0.5 to 2.0, with the average folding error and absolute average folding error for all concentration–time data points reaching 0.89 and 1.38, respectively. Importantly, for pregnant patients, OSE administration is recommended to be tailored by CES1 genotype, cirrhosis severity, and pregnancy trimester, to achieve post‐dosing AUC levels comparable to those of the non‐pregnant reference population. This integrated pregnancy PBPK model enables us to comprehensively and extensively explore the PK characteristics of OSE and OSC in pregnant women under complex scenarios, thereby providing valuable guidance for clinical applications and precise management of influenza during pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OseltamivirCarboxylic Ester HydrolasesModels, BiologicalAntiviral AgentsLiver CirrhosisHumansFemalePregnancyAdultPolymorphism, GeneticInfluenza, HumanPregnancy Complications, InfectiousYoung AdultArea Under CurveGenotype

Stichwörter der Autor:innen

carboxylesterase 1hepatic cirrhosisoseltamivirphysiologically based pharmacokineticpregnant women

Substanzen

OseltamivirCarboxylic Ester HydrolasesCES1 protein, humanAntiviral Agents

Autor:innen und Institutionen

  • Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

ORCID-Profile: Jianwen Xu, Yuewen Chen

Förderung

  • Innovation of Science and Technology, Fujian Province
  • Natural Science Foundation of Fujian Province
  • Fujian Provincial Health Technology

Zitieren

APA

Xu, J., Zhang, S., Zhou, P., Zhan, Z., Zhou, S., Chen, Y., Lin, R., & Lin, C. (2026). Physiologically Based Pharmacokinetic Modeling to Predict the Exposure and Provide Dosage Regimens of Oseltamivir in Pregnant Women with Comorbid CES1 Polymorphism and Hepatic Cirrhosis. The Journal of Clinical Pharmacology, 66(11). https://doi.org/10.1002/jcph.70285

Vancouver

Xu J, Zhang S, Zhou P, Zhan Z, Zhou S, Chen Y, et al. Physiologically Based Pharmacokinetic Modeling to Predict the Exposure and Provide Dosage Regimens of Oseltamivir in Pregnant Women with Comorbid CES1 Polymorphism and Hepatic Cirrhosis. The Journal of Clinical Pharmacology. 2026;66(11). doi:10.1002/jcph.70285

BibTeX
@article{Xu2026,
  author = {Xu, Jianwen and Zhang, Shoutian and Zhou, Peilin and Zhan, Zhikun and Zhou, Shuifang and Chen, Yuewen and Lin, Rongfang and Lin, Cuihong},
  title = {Physiologically Based Pharmacokinetic Modeling to Predict the Exposure and Provide Dosage Regimens of Oseltamivir in Pregnant Women with Comorbid CES1 Polymorphism and Hepatic Cirrhosis},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  volume = {66},
  number = {11},
  doi = {10.1002/jcph.70285}
}
Kostenlos starten →